These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 10882399)
1. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Maack C; Cremers B; Flesch M; Höper A; Südkamp M; Böhm M Br J Pharmacol; 2000 Jul; 130(5):1131-9. PubMed ID: 10882399 [TBL] [Abstract][Full Text] [Related]
2. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Brixius K; Bundkirchen A; Bölck B; Mehlhorn U; Schwinger RH Br J Pharmacol; 2001 Aug; 133(8):1330-8. PubMed ID: 11498519 [TBL] [Abstract][Full Text] [Related]
3. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium. Maack C; Tyroller S; Schnabel P; Cremers B; Dabew E; Südkamp M; Böhm M Br J Pharmacol; 2001 Apr; 132(8):1817-26. PubMed ID: 11309254 [TBL] [Abstract][Full Text] [Related]
4. Bucindolol exerts agonistic activity on the propranolol-insensitive state of beta1-adrenoceptors in human myocardium. Bundkirchen A; Brixius K; Bölck B; Schwinger RH J Pharmacol Exp Ther; 2002 Mar; 300(3):794-801. PubMed ID: 11861783 [TBL] [Abstract][Full Text] [Related]
5. Receptor pharmacology of carvedilol in the human heart. Bristow MR; Larrabee P; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port JD; Müller-Beckmann B J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S68-80. PubMed ID: 1378154 [TBL] [Abstract][Full Text] [Related]
6. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor. Maack C; Böhm M; Vlaskin L; Dabew E; Lorenz K; Schäfers HJ; Lohse MJ; Engelhardt S Circulation; 2003 Jul; 108(3):348-53. PubMed ID: 12847069 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes. Flesch M; Ettelbrück S; Rosenkranz S; Maack C; Cremers B; Schlüter KD; Zolk O; Böhm M Cardiovasc Res; 2001 Feb; 49(2):371-80. PubMed ID: 11164847 [TBL] [Abstract][Full Text] [Related]
8. Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium. Molenaar P; Christ T; Berk E; Engel A; Gillette KT; Galindo-Tovar A; Ravens U; Kaumann AJ Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):629-40. PubMed ID: 24668024 [TBL] [Abstract][Full Text] [Related]
9. Differential effects of bucindolol and carvedilol on noradenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats. Pönicke K; Heinroth-Hoffmann I; Brodde OE J Pharmacol Exp Ther; 2002 Apr; 301(1):71-6. PubMed ID: 11907159 [TBL] [Abstract][Full Text] [Related]
10. Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart. Molenaar P; Christ T; Ravens U; Kaumann A Cardiovasc Res; 2006 Jan; 69(1):128-39. PubMed ID: 16225854 [TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. Hanada K; Asari K; Saito M; Kawana J; Mita M; Ogata H Eur J Pharmacol; 2008 Jul; 589(1-3):194-200. PubMed ID: 18534575 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. Willette RN; Aiyar N; Yue TL; Mitchell MP; Disa J; Storer BL; Naselsky DP; Stadel JM; Ohlstein EH; Ruffolo RR J Pharmacol Exp Ther; 1999 Apr; 289(1):48-53. PubMed ID: 10086986 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of bucindolol in human ventricular myocardium. Hershberger RE; Wynn JR; Sundberg L; Bristow MR J Cardiovasc Pharmacol; 1990 Jun; 15(6):959-67. PubMed ID: 1694919 [TBL] [Abstract][Full Text] [Related]
16. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. Ahmed A Eur J Heart Fail; 2003 Dec; 5(6):709-15. PubMed ID: 14675848 [TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with carvedilol improves Ca(2+)-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium. Brixius K; Lu R; Boelck B; Grafweg S; Hoyer F; Pott C; Mehlhorn U; Bloch W; Schwinger RH J Pharmacol Exp Ther; 2007 Jul; 322(1):222-7. PubMed ID: 17409273 [TBL] [Abstract][Full Text] [Related]
18. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. Asano K; Zisman LS; Yoshikawa T; Headley V; Bristow MR; Port JD J Cardiovasc Pharmacol; 2001 Jun; 37(6):678-91. PubMed ID: 11392464 [TBL] [Abstract][Full Text] [Related]
19. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Flesch M; Maack C; Cremers B; Bäumer AT; Südkamp M; Böhm M Circulation; 1999 Jul; 100(4):346-53. PubMed ID: 10421593 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Willette RN; Mitchell MP; Ohlstein EH; Lukas MA; Ruffolo RR Pharmacology; 1998 Jan; 56(1):30-6. PubMed ID: 9467185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]